PRIMARY OBJECTIVES:
I. To determine the frequency of topoisomerase 2-alpha (TOPO2A) gene copy number alterations
(including deletions, gains, and amplification), immunohistochemical expression, and
chromosome 17 polysomy in tumor tissue samples from patients with advanced or recurrent
endometrial carcinoma treated with anthracycline-based therapy on Gynecologic Oncology Group
(GOG)-0177.
II. To assess the relationship between TOPO2A gene copy number alterations, TOPO2A protein
expression, chromosome 17 polysomy, and human epidermal growth factor receptor 2 (HER2)
status in tumor tissue samples from these patients.
III. To assess the association between TOPO2A status (TOPO2A gene copy number alterations and
TOPO2A protein expression), or chromosome 17 polysomy and clinical covariates (e.g., age,
race/ethnicity, cell type, histologic grade, disease stage, regimen type).
IV. To assess the association between TOPO2A status or chromosome 17 polysomy with measures
of clinical outcome including response, progression-free survival, and overall survival of
patients treated with this regimen.
V. To evaluate the potential identification of cut points for TOPO2A protein expression with
potential prognostic value in patients treated with this regimen.
OUTLINE:
Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and
expression and chromosome 17 polysomy by fluorescent in situ hybridization (FISH) and
immunohistochemistry (IHC). Clinical information associated with each endometrial carcinoma
sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen
type) is also collected.
